Organization (Hospital)
Shanghai Public Health Clinical Center
ClinicalTrials.gov lists Shanghai Public Health Clinical Center as lead sponsor of 38 trials. It has 36 active development programs and 19 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 7 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Shanghai Public Health Clinical Center: 38 lead-sponsored trials and 1 legal-entity registration.
Disease areas (52)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 20 |
| Tuberculosis | 11 |
| Acquired Immunodeficiency Syndrome | 9 |
| Fibrosis | 9 |
| Hepatitis B | 8 |
Showing 5 of 52 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 7 |
| 2020 | 11 |
| 2019 | 5 |
| 2018 | 9 |
| 2017 | 5 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (36)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Infusion of iNKT cells and CD8+T cells | Kidney Neoplasms | Phase 1/2 | 1 |
| Infusion of iNKT cells and CD8+T cells | Carcinoma, Hepatocellular | Phase 1/2 | 1 |
| Infusion of iNKT cells and CD8+T cells | Carcinoma, Renal Cell | Phase 1/2 | 1 |
| Infusion of iNKT cells and CD8+T cells | Carcinoma, Non-Small-Cell Lung | Phase 1/2 | 1 |
| Infusion of iNKT cells and CD8+T cells | Liver Neoplasms | Phase 1/2 | 1 |
Showing 5 of 36 active programs.
Approved assets (19)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Efavirenz | 2 |
| LAMIVUDINE | 2 |
| Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG) | 1 |
| TDF-based triple ART regimen switching to B/F/TAF | 1 |
| RIF | 1 |
Showing 5 of 19 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 80% hit target (n=5) | 60% on time (n=5) |
Journals published in (95)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 14 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 6 |
| Infection and immunity | 5 |
| Vaccine | 5 |
| American journal of respiratory and critical care medicine | 3 |
Showing 5 of 95 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 2 | 2025-03-18 |
Organization relationships (93)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Co sponsors trial with | 4 |
| The Second Hospital of Nanjing Medical University | Co sponsors trial with | 4 |
| Beijing Ditan Hospital | Co sponsors trial with | 4 |
| Public Health Clinical Center of Chengdu | Co sponsors trial with | 3 |
| Renji Hospital | Co sponsors trial with | 3 |
Showing 5 of 93 relationships.
Latest dated events (80)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 80 events.
Biomarker capability evidence (143)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABHD5 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 143 evidence rows.
Biomarkers this organization publishes on (162)
Shown in this order: most publications first.
Showing 5 of 162 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.